Abstract
Renin-angiotensin-aldosterone system inhibitors (RAASis) are beneficial and recommended for patients with chronic kidney disease (CKD) and type 2 diabetes mellitus (T2DM). However, hyperkalemia (HK) often limits RAASi therapy. The OPAL-HK [NCT01810939] trial found that patiromer normalized serum potassium (s-K+) and prevent HK recurrence compared with placebo. This article discusses a poster investigating the prespecified analysis of the subgroup with T2DM in OPAL-HK.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
